<?xml version="1.0" encoding="UTF-8"?>
<html xmlns="http://www.w3.org/1999/xhtml">
 <head charset="UTF-8"/>
 <style> * { font-family : helvetica;} .font19 { font-size : 19; } .font10 { font-size : 10; } .font27 { font-size : 27; } .font11 { font-size : 11; } .font12 { font-size : 12; } .font13 { font-size : 13; } .font30 { font-size : 30; } .font14 { font-size : 14; } .font15 { font-size : 15; }</style>
 <body>
  <p>
   <span class="font30">and </span>
   <span class="font27">the </span>
   <span class="font19">for </span>
   <span class="font15">delivery </span>
   <span class="font15">with </span>
   <span class="font14">antibody </span>
   <span class="font13">DNA </span>
   <span class="font13">expression </span>
   <span class="font13">are </span>
   <span class="font13">[]. </span>
   <span class="font13">vivo </span>
   <span class="font12">against </span>
   <span class="font12">The </span>
   <span class="font12">have </span>
   <span class="font12">that </span>
   <span class="font12">mRNA </span>
   <span class="font12">virus </span>
   <span class="font12">gene </span>
   <span class="font12">studies </span>
   <span class="font11">human </span>
   <span class="font11">mAb </span>
   <span class="font11">al. </span>
   <span class="font11">antibodies </span>
   <span class="font11">can </span>
   <span class="font11">from </span>
   <span class="font11">been </span>
   <span class="font11">this </span>
   <span class="font11">has </span>
   <span class="font11">plasmid </span>
   <span class="font11">DMAb </span>
   <span class="font11">This </span>
   <span class="font11">potential </span>
   <span class="font11">synthetic </span>
   <span class="font11">into </span>
   <span class="font11">mice </span>
   <span class="font11">such </span>
   <span class="font11">{background </span>
   <span class="font11">development </span>
   <span class="font11">pDNA-mAb </span>
   <span class="font11">vector </span>
   <span class="font11">these </span>
   <span class="font11">levels </span>
   <span class="font11">pDNA-mAbs </span>
   <span class="font11">vectors </span>
   <span class="font11">viral </span>
   <span class="font11">was </span>
   <span class="font11">administration </span>
   <span class="font11">important </span>
   <span class="font11">study </span>
   <span class="font11">were </span>
   <span class="font10">AAV </span>
   <span class="font10">demonstrated </span>
   <span class="font10">Î¼g/mL </span>
   <span class="font10">[], </span>
   <span class="font10">margin </span>
   <span class="font10">therapy </span>
   <span class="font10">using </span>
   <span class="font10">However, </span>
   <span class="font10">clinical </span>
   <span class="font10">immune </span>
   <span class="font10">monoclonal </span>
   <span class="font10">protection </span>
   <span class="font10">will </span>
   <span class="font10">{border-style </span>
   <span class="font10">bispecific </span>
   <span class="font10">mouse </span>
   <span class="font10">rapid </span>
   <span class="font10">RNA </span>
   <span class="font10">additional </span>
   <span class="font10">also </span>
   <span class="font10">both </span>
   <span class="font10">challenge </span>
   <span class="font10">data </span>
   <span class="font10">influenza </span>
   <span class="font10">px;} </span>
   <span class="font10">recombinant </span>
   <span class="font10">safety </span>
   <span class="font10">which </span>
   <span class="font10">#ffffff;} </span>
   <span class="font10">DNA-encoded </span>
   <span class="font10">different </span>
   <span class="font10">more </span>
   <span class="font10">new </span>
   <span class="font10">nucleic </span>
   <span class="font10">targeting </span>
   <span class="font10">These </span>
   <span class="font10">delivered </span>
   <span class="font10">delivery, </span>
   <span class="font10">including </span>
   <span class="font10">infectious </span>
   <span class="font10">through </span>
   <span class="font10">animal </span>
   <span class="font10">being </span>
   <span class="font10">first </span>
   <span class="font10">high </span>
   <span class="font10">highly </span>
   <span class="font10">not </span>
   <span class="font10">other </span>
   <span class="font10">protein </span>
   <span class="font10">reported </span>
   <span class="font10">significant </span>
   <span class="font10">IgG </span>
   <span class="font10">acid </span>
   <span class="font10">biologics </span>
   <span class="font10">cells </span>
   <span class="font10">days </span>
   <span class="font10">disease </span>
   <span class="font10">engineered </span>
   <span class="font10">evaluated </span>
   <span class="font10">many </span>
   <span class="font10">over </span>
   <span class="font10">vaccine </span>
   <span class="font10">well </span>
   <span class="font10">DMAbs </span>
   <span class="font10">Ref. </span>
   <span class="font10">cancer </span>
   <span class="font10">following </span>
   <span class="font10">impact </span>
   <span class="font10">integration </span>
   <span class="font10">mRNA-mAb </span>
   <span class="font10">may </span>
   <span class="font10">modifications </span>
   <span class="font10">observed </span>
   <span class="font10">platforms </span>
   <span class="font10">similar </span>
   <span class="font10">treatment </span>
   <span class="font10">via </span>
   <span class="font10">(reviewed </span>
   <span class="font10">Gene </span>
   <span class="font10">approaches </span>
   <span class="font10">combination </span>
   <span class="font10">further </span>
   <span class="font10">hyaluronidase </span>
   <span class="font10">infection </span>
   <span class="font10">mAbs </span>
   <span class="font10">muscle </span>
   <span class="font10">neutralizing </span>
   <span class="font10">strategies </span>
   <span class="font10">They </span>
   <span class="font10">after </span>
   <span class="font10">approach </span>
   <span class="font10">cell </span>
   <span class="font10">dose </span>
   <span class="font10">doses </span>
   <span class="font10">events </span>
   <span class="font10">field </span>
   <span class="font10">manufacturing </span>
   <span class="font10">platform </span>
   <span class="font10">preclinical </span>
   <span class="font10">promising </span>
   <span class="font10">requires </span>
   <span class="font10">showed </span>
   <span class="font10">single </span>
   <span class="font10">then </span>
   <span class="font10">trial </span>
   <span class="font10">tumor </span>
   <span class="font10">Zika </span>
   <span class="font10">[]). </span>
   <span class="font10">activity </span>
   <span class="font10">before </span>
   <span class="font10">demonstrating </span>
   <span class="font10">early </span>
   <span class="font10">fully </span>
   <span class="font10">improve </span>
   <span class="font10">injection </span>
   <span class="font10">lethal </span>
   <span class="font10">models </span>
   <span class="font10">protected </span>
   <span class="font10">studies, </span>
   <span class="font10">system </span>
   <span class="font10">there </span>
   <span class="font10">traditional </span>
   <span class="font10">Delivery </span>
   <span class="font10">Plasmid </span>
   <span class="font10">Synthetic </span>
   <span class="font10">T-cell </span>
   <span class="font10">broadly </span>
   <span class="font10">compared </span>
   <span class="font10">followed </span>
   <span class="font10">genome </span>
   <span class="font10">however, </span>
   <span class="font10">immunogenicity </span>
   <span class="font10">leading </span>
   <span class="font10">natural </span>
   <span class="font10">only </span>
   <span class="font10">people </span>
   <span class="font10">phase </span>
   <span class="font10">sequence </span>
   <span class="font10">technologies </span>
   <span class="font10">vaccines </span>
   <span class="font10">would </span>
   <span class="font10">Additional </span>
   <span class="font10">Fig. </span>
   <span class="font10">HIV </span>
   <span class="font10">LNP </span>
   <span class="font10">advanced </span>
   <span class="font10">adverse </span>
   <span class="font10">cost </span>
   <span class="font10">delivery. </span>
   <span class="font10">dengue </span>
   <span class="font10">due </span>
   <span class="font10">encoded </span>
   <span class="font10">encoding </span>
   <span class="font10">engineering </span>
   <span class="font10">evaluating </span>
   <span class="font10">gene-encoded </span>
   <span class="font10">healthy </span>
   <span class="font10">initial </span>
   <span class="font10">innate </span>
   <span class="font10">long </span>
   <span class="font10">must </span>
   <span class="font10">novel </span>
   <span class="font10">overall </span>
   <span class="font10">parallel </span>
   <span class="font10">patients </span>
   <span class="font10">production </span>
   <span class="font10">protective </span>
   <span class="font10">protects </span>
   <span class="font10">provide </span>
   <span class="font10">px; </span>
   <span class="font10">receptor </span>
   <span class="font10">responses </span>
   <span class="font10">several </span>
   <span class="font10">systemic </span>
   <span class="font10">their </span>
   <span class="font10">they </span>
   <span class="font10">trials </span>
   <span class="font10">weeks </span>
   <span class="font10">when </span>
   <span class="font10">wt-DMAb </span>
   <span class="font10">{font-family </span>
   <span class="font10">Both </span>
   <span class="font10">Clin </span>
   <span class="font10">animals </span>
   <span class="font10">anti-HIV </span>
   <span class="font10">antigen </span>
   <span class="font10">approved </span>
   <span class="font10">but </span>
   <span class="font10">checkpoint </span>
   <span class="font10">control </span>
   <span class="font10">currently </span>
   <span class="font10">date, </span>
   <span class="font10">described </span>
   <span class="font10">drug </span>
   <span class="font10">efficacy </span>
   <span class="font10">evaluate </span>
   <span class="font10">font-size </span>
   <span class="font10">increase </span>
   <span class="font10">informative </span>
   <span class="font10">less </span>
   <span class="font10">likely </span>
   <span class="font10">mice. </span>
   <span class="font10">most </span>
   <span class="font10">multiple </span>
   <span class="font10">non-human </span>
   <span class="font10">non-viral </span>
   <span class="font10">optimized </span>
   <span class="font10">peak </span>
   <span class="font10">rapidly </span>
   <span class="font10">response </span>
   <span class="font10">results </span>
   <span class="font10">specific </span>
   <span class="font10">studied </span>
   <span class="font10">studies. </span>
   <span class="font10">supporting </span>
   <span class="font10">target </span>
   <span class="font10">within </span>
   <span class="font10">(Fig.Â </span>
   <span class="font10">Accessed </span>
   <span class="font10">Antibodies </span>
   <span class="font10">B-cell </span>
   <span class="font10">Centers </span>
   <span class="font10">Drug </span>
   <span class="font10">Ebola </span>
   <span class="font10">For </span>
   <span class="font10">Infect </span>
   <span class="font10">Therefore, </span>
   <span class="font10">achieve </span>
   <span class="font10">acid-encoded </span>
   <span class="font10">administered </span>
   <span class="font10">administration. </span>
   <span class="font10">antibodies. </span>
   <span class="font10">biologics, </span>
   <span class="font10">biologics. </span>
   <span class="font10">challenges </span>
   <span class="font10">could </span>
   <span class="font10">demonstrate </span>
   <span class="font10">directly </span>
   <span class="font10">double; </span>
   <span class="font10">duration </span>
   <span class="font10">electroporation </span>
   <span class="font10">evaluation </span>
   <span class="font10">expressed </span>
   <span class="font10">expression. </span>
   <span class="font10">half-life </span>
   <span class="font10">higher </span>
   <span class="font10">infection. </span>
   <span class="font10">limit </span>
   <span class="font10">mAb, </span>
   <span class="font10">mRNA-encoded </span>
   <span class="font10">messenger </span>
   <span class="font10">model </span>
   <span class="font10">modified </span>
   <span class="font10">need </span>
   <span class="font10">optimizations </span>
   <span class="font10">patient </span>
   <span class="font10">platforms. </span>
   <span class="font10">pre-treatment </span>
   <span class="font10">prevent </span>
   <span class="font10">providing </span>
   <span class="font10">rabies </span>
   <span class="font10">receiving </span>
   <span class="font10">recent </span>
   <span class="font10">represent </span>
   <span class="font10">serum </span>
   <span class="font10">shown </span>
   <span class="font10">stability </span>
   <span class="font10">still </span>
   <span class="font10">study, </span>
   <span class="font10">survival </span>
   <span class="font10">than </span>
   <span class="font10">translation </span>
   <span class="font10">unique </span>
   <span class="font10">Âµg/mL </span>
   <span class="font10">â€" </span>
   <span class="font10">â€² </span>
   <span class="font10">(AAV) </span>
   <span class="font10">Ebolavirus </span>
   <span class="font10">Health </span>
   <span class="font10">Institutes </span>
   <span class="font10">More </span>
   <span class="font10">Nucleic </span>
   <span class="font10">Other </span>
   <span class="font10">Patel </span>
   <span class="font10">Ther./hum.. </span>
   <span class="font10">Ther./j.ymthe... </span>
   <span class="font10">Viral </span>
   <span class="font10">While </span>
   <span class="font10">ZMapp </span>
   <span class="font10">achieved </span>
   <span class="font10">adeno-associated </span>
   <span class="font10">advantages </span>
   <span class="font10">all </span>
   <span class="font10">alternative </span>
   <span class="font10">anti-Zika </span>
   <span class="font10">anti-influenza </span>
   <span class="font10">applications </span>
   <span class="font10">approximately </span>
   <span class="font10">area </span>
   <span class="font10">article </span>
   <span class="font10">associated </span>
   <span class="font10">border-color </span>
   <span class="font10">border-width </span>
   <span class="font10">cells. </span>
   <span class="font10">clinic </span>
   <span class="font10">clinic. </span>
   <span class="font10">cold-chain </span>
   <span class="font10">combined </span>
   <span class="font10">costs </span>
   <span class="font10">direct </span>
   <span class="font10">emerging </span>
   <span class="font10">estimated </span>
   <span class="font10">few </span>
   <span class="font10">formulated </span>
   <span class="font10">functional </span>
   <span class="font10">global </span>
   <span class="font10">greatly </span>
   <span class="font10">group </span>
   <span class="font10">had </span>
   <span class="font10">humans </span>
   <span class="font10">immunity </span>
   <span class="font10">include </span>
   <span class="font10">individuals </span>
   <span class="font10">ipilimumab </span>
   <span class="font10">its </span>
   <span class="font10">kinase </span>
   <span class="font10">least </span>
   <span class="font10">limited </span>
   <span class="font10">long-term </span>
   <span class="font10">mRNA-mAbs </span>
   <span class="font10">mRNA. </span>
   <span class="font10">nivolumab </span>
   <span class="font10">original </span>
   <span class="font10">pandemic </span>
   <span class="font10">pharmacokinetics </span>
   <span class="font10">potent </span>
   <span class="font10">primates </span>
   <span class="font10">received </span>
   <span class="font10">repeat </span>
   <span class="font10">required </span>
   <span class="font10">resistant </span>
   <span class="font10">retrotransposons </span>
   <span class="font10">risk </span>
   <span class="font10">same </span>
   <span class="font10">sequences </span>
   <span class="font10">serotype </span>
   <span class="font10">short </span>
   <span class="font10">show </span>
   <span class="font10">skeletal </span>
   <span class="font10">small </span>
   <span class="font10">solid; </span>
   <span class="font10">technology </span>
   <span class="font10">three </span>
   <span class="font10">time </span>
   <span class="font10">two </span>
   <span class="font10">use </span>
   <span class="font10">very </span>
   <span class="font10">vitro </span>
   <span class="font10">work </span>
   <span class="font10">year </span>
   <span class="font10">{font-style </span>
   <span class="font10">{font-weight </span>
   <span class="font10">(Fig. </span>
   <span class="font10">Additionally, </span>
   <span class="font10">Although </span>
   <span class="font10">Antibody </span>
   <span class="font10">BiTE </span>
   <span class="font10">BsMAb </span>
   <span class="font10">Building </span>
   <span class="font10">Commons </span>
   <span class="font10">Control </span>
   <span class="font10">Creative </span>
   <span class="font10">David </span>
   <span class="font10">Disease </span>
   <span class="font10">Foundation </span>
   <span class="font10">Gates </span>
   <span class="font10">HIV- </span>
   <span class="font10">LALA-DMAb </span>
   <span class="font10">Melinda </span>
   <span class="font10">National </span>
   <span class="font10">Several </span>
   <span class="font10">Transl </span>
   <span class="font10">U.S. </span>
   <span class="font10">Vaccine </span>
   <span class="font10">Vivo </span>
   <span class="font10">Yes </span>
   <span class="font10">active </span>
   <span class="font10">adaptive </span>
   <span class="font10">adenoviral </span>
   <span class="font10">al.A </span>
   <span class="font10">al.In </span>
   <span class="font10">amino </span>
   <span class="font10">among </span>
   <span class="font10">anti-dengue </span>
   <span class="font10">anti-rabies </span>
   <span class="font10">antibodies: </span>
   <span class="font10">antibody, </span>
   <span class="font10">antibody. </span>
   <span class="font10">based </span>
   <span class="font10">biological </span>
   <span class="font10">bold </span>
   <span class="font10">cases </span>
   <span class="font10">caspase </span>
   <span class="font10">cells, </span>
   <span class="font10">cellular </span>
   <span class="font10">chain </span>
   <span class="font10">challenged </span>
   <span class="font10">courier; </span>
   <span class="font10">current </span>
   <span class="font10">dasatinib </span>
   <span class="font10">days. </span>
   <span class="font10">demonstration </span>
   <span class="font10">detectable </span>
   <span class="font10">diseases </span>
   <span class="font10">diseases. </span>
   <span class="font10">electroporation, </span>
   <span class="font10">em; </span>
   <span class="font10">enhanced </span>
   <span class="font10">escalation </span>
   <span class="font10">exciting </span>
   <span class="font10">express </span>
   <span class="font10">expressing </span>
   <span class="font10">field. </span>
   <span class="font10">first-in-human </span>
   <span class="font10">focused </span>
   <span class="font10">formulation </span>
   <span class="font10">formulation, </span>
   <span class="font10">four </span>
   <span class="font10">functionality </span>
   <span class="font10">genetic </span>
   <span class="font10">identified </span>
   <span class="font10">immunoglobulin </span>
   <span class="font10">improved </span>
   <span class="font10">includes </span>
   <span class="font10">increased </span>
   <span class="font10">increases </span>
   <span class="font10">infusion </span>
   <span class="font10">inhibitor </span>
   <span class="font10">interesting </span>
   <span class="font10">level </span>
   <span class="font10">lower </span>
   <span class="font10">macaques </span>
   <span class="font10">material </span>
   <span class="font10">mediated </span>
   <span class="font10">million </span>
   <span class="font10">mutation </span>
   <span class="font10">neonatal </span>
   <span class="font10">normal </span>
   <span class="font10">ofâ€‰&amp;gt;â€‰Â </span>
   <span class="font10">one </span>
   <span class="font10">optimizations, </span>
   <span class="font10">others </span>
   <span class="font10">others. </span>
   <span class="font10">part </span>
   <span class="font10">people. </span>
   <span class="font10">performed </span>
   <span class="font10">possibility </span>
   <span class="font10">prevention </span>
   <span class="font10">previously </span>
   <span class="font10">primary </span>
   <span class="font10">product </span>
   <span class="font10">progress </span>
   <span class="font10">promoter </span>
   <span class="font10">protect </span>
   <span class="font10">pt;} </span>
   <span class="font10">recently, </span>
   <span class="font10">receptors </span>
   <span class="font10">regimen </span>
   <span class="font10">related </span>
   <span class="font10">resulting </span>
   <span class="font10">rhesus </span>
   <span class="font10">routes </span>
   <span class="font10">safety, </span>
   <span class="font10">seasonal </span>
   <span class="font10">serious </span>
   <span class="font10">showing </span>
   <span class="font10">site </span>
   <span class="font10">start </span>
   <span class="font10">successful </span>
   <span class="font10">surface </span>
   <span class="font10">take </span>
   <span class="font10">therefore </span>
   <span class="font10">tissues </span>
   <span class="font10">tolerability, </span>
   <span class="font10">total </span>
   <span class="font10">toxicity </span>
   <span class="font10">transcribed </span>
   <span class="font10">transfer </span>
   <span class="font10">under </span>
   <span class="font10">uptake </span>
   <span class="font10">utilizing </span>
   <span class="font10">vectors, </span>
   <span class="font10">viruses </span>
  </p>
 </body>
</html>
